The 4th Stat4Onc Annual Symposium (2021)
Symposium Objectives
The Stat4Onc Annual Symposium is a venue for interdisciplinary dialogue among clinical and quantitative scientists about cancer clinical trials. We seek participation by researchers from academia, industry, and regulatory agencies to share new research, discuss novel ideas, ask questions, and provide solutions for cancer clinical trials. Oncologists and statisticians can exchange views on trial design and conduct, drug development, and translation to patient care. Because of the current COVID-19 pandemic situation, the 4th Stat4Onc Annual Symposium will be help as an online conference. Topics for this symposium include big data and genomics, novel dose-finding designs, umbrella/basket designs, drug combinations, immune-based oncology, and engagement of under-representative population in oncology research.
We want to thank to the NCI’s support to this conference through NCI R13 grant mechanism, our non-profit collaborations with BBSW and DahShu, and generous industry sponsorship from Abbvie, Beigene, Gilead, Nektar and Sanofi. Industry sponsors who provided funds have had no input into the content and materials used in this conference.
Registration
Link information will be provided in your email to sign in to Whova one week prior to the conference date.
Get Whova Now
Get our official
conference app,
Get the most out of the app and have a more productive experience!
1
NAVIGATE the event agenda and logistics, even without Wi-Fi or data. Access useful information like ridesharing and local attractions through the Community Board
2
NETWORK effectively. Plan whom to meet by exploring attendee profiles and sending out messages
3
PARTICIPATE in event activities through session likes, comments, ratings, live polling, tweeting, and more
Add to my calendar
Conference History
The idea of a unique conference that brings statisticians and oncologists together to discuss the challenges in oncology was initiated in 2015 during discussions between Yuan Ji (University of Chicago) and Professors Ying Lu (Stanford). The first symposium was held in 2017 at Stanford University . It was sponsored jointly by Stanford University and the University of Chicago. The second symposium was held in 2018 at the University of Chicago. At that time, we extended our partnership to include the University of Connecticut and chose OncoStat as the symposium name. The third symposium was held in 2019 at the University of Connecticut and renamed our symposium Stat4Onc. In 2020, we further extended our partnership to include the Oregon Health and Science University. This symposium is intended to be an annual event that rotates its location between Stanford University, the University of Chicago, the University of Connecticut and the Oregon Health Science University. Due to Covid-19 pandemic, the 2020 Symposium was postponed to 2021. For the safety of our participants and in view of current pandemic condition, the 2021 Symposium will be held online on May 6-8, 2021.
Click here to THE 3rd STAT4ONC ANNUAL SYMPOSIUM (2019)
Click here to THE 2nd STAT4ONC ANNUAL SYMPOSIUM (2018)
Click here to THE 1st STAT4ONC ANNUAL SYMPOSIUM (2017)
The 3rd Stat4Onc Annual Symposium
James Reimann is Vice President and Global Head of Data Strategy & Delivery at Genentech/Roche. Until November 2020, James was VP and Global Head of Oncology Biostatistics & Patient Centered Outcomes Research (PCOR) and had spent 20 years as a Biostatistician in Oncology research. In his current role, he oversees "data as an asset" for the entire Genentech/Roche pipeline, including capabilities coming from a variety of disciplines (CDM, Data Standards & Governance, Data Curation & Integration, Data Privacy & Sharing), reflecting a shift towards viewing patient data as a strategic asset in the age of digital health. He holds a PhD in Statistics from the University of California, Berkeley.
Peter Bross is acting Chief of Oncology Branch and clinical team leader in the FDA Center for Biological Evaluation and Research (CBER), Office of Tissue and Advanced Therapies (OTAT) and previously worked as a clinical reviewer in the Division of Oncology Drug Products in the Center for Drug Evaluation and Research (CDER). Over 20 years at FDA, Dr. Bross has gained expertise in the design and analysis of clinical oncology trials of cellular, tissue and gene therapies, especially cancer vaccines, combination therapies, and companion diagnostics. As a regulatory reviewer, he has reviewed new molecular entities for marketing approvals in solid tumors and hematological malignancies, including oncolytic viruses, cellular immunotherapies, targeted kinase inhibitors, proteasome inhibitors and an antibody-drug conjugate. He has presented FDA perspectives at professional meetings and review findings at FDA advisory committee meetings and has authored several manuscripts. Dr. Bross is a graduate of University of Virginia Medical School and trained in Hematology and Oncology at The George Washington University and has been at FDA since 1999.
Dr. Brigitte Widemann is a pediatric oncologist with the primary interest of developing effective therapies for children and adults with genetic tumor predisposition syndromes, such as neurofibromatosis type 1 (NF1), and rare solid tumors through innovative clinical trial design. Dr. Widemann currently serves as the head of the Pharmacology & Experimental Therapeutics Section and as Chief of NCI’s Pediatric Oncology Branch.
Anticancer drug discovery and development are moving towards a more rational and targeted approach. The application of new molecularly targeted agents to the treatment of childhood cancers and neurofibromatosis type 1 (NF1) is a research objective of the Pharmacology & Experimental Therapeutics Section (PETS). In addition to studying the pharmacology, pharmacokinetics, pharmacodynamics, and toxicities of these novel agents, it is also a goal of the PETS to evaluate novel clinical trial designs and trial endpoints, which may be more applicable for molecularly targeted agents.
Dr. Laura Esserman is Professor of Surgery and Radiology at the University of California, San Francisco (UCSF) and director of the UCSF Breast Care Clinic. Her work in breast cancer spans the spectrum from basic science to public policy issues, and the impact of both on the delivery of clinical care. Dr. Esserman is recognized as a thought leader in cancer screening and over-diagnosis, as well as innovative clinical trial design. She led the creation of the University of California-wide Athena Breast Health Network, a learning system designed to integrate clinical care and research as it follows 150,000 women from screening through treatment and outcomes. The Athena Network launched the PCORI-funded Wisdom Study, which tests a personalized approach to breast cancer screening in 100,000 women. She is also a leader of the innovative I-SPY TRIAL model, designed to accelerate the identification and approval of effective new agents for women with high risk breast cancers.
Christina Yau, PhD, is Association Professor of Surgery at the University of California, San Francisco. She is a bioinformatician with extensive experience in analyzing high dimensional biological data, such as gene expression and inferred pathway activity data, to address important questions in translational cancer research. She actively participated in the Cancer Genome Atlas (TCGA) Research Network efforts to comprehensively characterize the molecular portraits of human cancers. She is a member of the I-SPY 2 Data Access and Publication Committee and Biomarker Working Group. 
Amanda Bruegl is a Citizen of Oneida Nation and is a Gynecologic Oncologist in the department of OB/Gyn at Oregon Health and Science University. She completed her fellowship in gynecologic oncology at MD Anderson Cancer Center and has been at OHSU since that time. She is the Associate Director of the Education Core for the Northwest Native American Center of Excellence, a recipient of the Robert Wood Johnson Harold Amos Minority Faculty Development Award, and has research interests in gynecologic cancer prevention in American Indian/Alaska Native women.